Abstract
Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19.
| Original language | English |
|---|---|
| Journal | Nature Reviews Immunology |
| Volume | 22 |
| Issue number | 2 |
| Pages (from-to) | 77-84 |
| Number of pages | 8 |
| ISSN | 1474-1733 |
| DOIs | |
| Publication status | Published - 02.2022 |
Funding
Research described in this article was supported (in part) by the Intramural Research Program of the US National Institute of Diabetes and Digestive and Kidney Diseases (project number ZIA/DK075149 (B.A).) and the US National Heart, Lung, and Blood Institute (project number ZIA/Hl006223 (C.K.)), by an FWO COVID-19 grant to B.N.L., and by a COVID-19 grant from the Fondazione Italcementi Cav. Lav. CARLO PESENTI to M.N.
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
DFG Research Classification Scheme
- 2.21-05 Immunology
Coronavirus related work
- Research on SARS-CoV-2 / COVID-19
